NCT02683317

Enteral Administration of Docosahexaenoic Acid to Prevent Retinopathy of Prematurity

Effect of Enteral Administration of Docosahexaenoic Acid on Development of the Retinopathy of Prematurity

• Status: Completed
• Phase: N/A
• Study type: Interventional
• Enrollment: 110 (actual)
• Sponsor: Coordinación de Investigación en Salud, Mexico · Other Government
• Sex: All
• Age: 60 Minutes – 2 Weeks
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to evaluate whether docosahexaenoic acid given by enteral feeding prevent retinopathy of prematurity and/or diminish its severity in preterm infants.

Detailed description

Preterm neonates who start receiving enteral feeding will receive the intervention with docosahexaenoic acid (DHA) since the first day and throughout 14 days, one dose per day. The opthalmic evaluation will be done after 4-5 weeks after birth and followed until 42-45 corrected gestational age.

Conditions

• Retinopathy of Prematurity

Interventions

Type	Name	Description
DIETARY_SUPPLEMENT	docosahexaenoic acid	Docosahexaenoic acid is a dietary supplement derived from algae.
DIETARY_SUPPLEMENT	sunflower oil	Sunflower similar to the excipient used in experimental group

Timeline

• Start date: 2016-02-22
• Primary completion: 2017-10-31
• Completion: 2017-10-31
• First posted: 2016-02-17
• Last updated: 2020-07-17

Locations

1 site across 1 country: Mexico